Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI303 vs Adalimumab in Active Ankylosing Spondylitis
NCT02893254Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Sep 2016
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of IBI303 in ankylosing spondylitis (AS), sponsored by Innovent Biologics. Started Sep 2016; status: completed.
02
Drugs
IBI303
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02893254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02893254.